Nasal Swabstick Supports Antibiotic Stewardship
By HospiMedica International staff writers Posted on 07 Mar 2018 |
Image: New research shows nasal decolonization kits ward against infection (Photo courtesy of PDI Healthcare).
A new nasal healthcare kit helps protect patients against surgical site infections (SSIs) and other hospital-acquired infections (HAIs).
The PDI Healthcare (Orangeburg, NY, USA) Profend Nasal Decolonization Kit is a clinician-applied swabstick that simplifies the decolonization process, reducing treatment time to a quick 60 seconds. While the dry-handle design minimizes grime, the small nasal swab offers easy application and enhanced comfort for patients. Each kit includes four pre-saturated swabs containing 0.75 ml of a 10% povidone-iodine solution, a broad-spectrum antiseptic proven effective against S. aureus and methicillin-resistant Staphylococcus aureus (MRSA), with no known pathogen resistance.
Nasal decolonization is an under-utilized method of infection control, since hand-to-nose contact occurs about every four minutes on average, often compromising hand hygiene and risking contamination; in fact, 80% of SSI pathogens can be tracked to the patient’s own nose. Studies show that infection control protocols which include nasal decolonization can reduced such infections by 44%, and in a clinical in-vivo study of healthy volunteers, Profend nasal swabsticks reduced S. aureus by 99.7% at one hour and 99.9% at 12 hours.
“Hospital acquired and surgical site infections are an increasingly complex and dynamic threat to the health of patients,” said Elise Tordella, vice president of marketing at PDI Healthcare. “Our response to this evolving hazard, the Profend Nasal Decolonization Kit, has been met with a positive clinical response as 90% of surveyed clinicians expressed a preference for it over other nasal PVP-iodine products.”
S. aureus (including MRSA) colonization of the nose is an endemic risk factor for infectious diseases such as bacteraemia and skin and soft tissue infections in many patient populations. In fact, most infections with S. aureus are caused by the patient's own bacteria, with autoinfection rates ranging between 76% and 86%. The density at which the anterior nares are colonized may be a further risk factor, with a 3-fold increase in SSIs reported in surgical patients with high concentrations of nasal S. aureus. Nasal decolonization is especially recommended in carriers of MRSA who are receiving antibiotic prophylaxis.
The PDI Healthcare (Orangeburg, NY, USA) Profend Nasal Decolonization Kit is a clinician-applied swabstick that simplifies the decolonization process, reducing treatment time to a quick 60 seconds. While the dry-handle design minimizes grime, the small nasal swab offers easy application and enhanced comfort for patients. Each kit includes four pre-saturated swabs containing 0.75 ml of a 10% povidone-iodine solution, a broad-spectrum antiseptic proven effective against S. aureus and methicillin-resistant Staphylococcus aureus (MRSA), with no known pathogen resistance.
Nasal decolonization is an under-utilized method of infection control, since hand-to-nose contact occurs about every four minutes on average, often compromising hand hygiene and risking contamination; in fact, 80% of SSI pathogens can be tracked to the patient’s own nose. Studies show that infection control protocols which include nasal decolonization can reduced such infections by 44%, and in a clinical in-vivo study of healthy volunteers, Profend nasal swabsticks reduced S. aureus by 99.7% at one hour and 99.9% at 12 hours.
“Hospital acquired and surgical site infections are an increasingly complex and dynamic threat to the health of patients,” said Elise Tordella, vice president of marketing at PDI Healthcare. “Our response to this evolving hazard, the Profend Nasal Decolonization Kit, has been met with a positive clinical response as 90% of surveyed clinicians expressed a preference for it over other nasal PVP-iodine products.”
S. aureus (including MRSA) colonization of the nose is an endemic risk factor for infectious diseases such as bacteraemia and skin and soft tissue infections in many patient populations. In fact, most infections with S. aureus are caused by the patient's own bacteria, with autoinfection rates ranging between 76% and 86%. The density at which the anterior nares are colonized may be a further risk factor, with a 3-fold increase in SSIs reported in surgical patients with high concentrations of nasal S. aureus. Nasal decolonization is especially recommended in carriers of MRSA who are receiving antibiotic prophylaxis.
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Latest Critical Care News
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration